U.S. markets closed

Xenetic Biosciences, Inc. (XBIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7300-0.0270 (-3.57%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close0.7570
Bid0.7300 x 1000
Ask0.7600 x 1200
Day's Range0.7300 - 0.8000
52 Week Range0.4540 - 5.6800
Avg. Volume211,083
Market Cap10.451M
Beta (5Y Monthly)2.54
PE Ratio (TTM)N/A
EPS (TTM)-0.5150
Earnings DateAug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for XBIO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Xenetic Biosciences, Inc.
    NKTR: What does Argus have to say about NKTR?NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $3.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more

    Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference

    Live Webcast Presentation on Wednesday, May 25th at 4:00 PM ETFRAMINGHAM, MA / ACCESSWIRE / May 18, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that Jeffrey F.


    Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

    \- Company completed recent transaction to expand oncology pipeline with in-licensing of DNase based platform comprising multiple therapeutic modalities\- DNase based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indications\- Focusing resources on advancing DNase based oncology platform in locally advanced or metastatic solid tumors towards Phase 1 clinical development\- Ended the quarter with $16.2 million of cash to fund operati


    Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities

    (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that it has entered into exclusive license and sublicense agreements with CLS Therapeutics ("CLS") to develop its interventional DNase based oncology platform, which is aimed at improving outcomes of existing treatments, including immunotherapies. Xenetic will host a conference call and webcast, today, Apr